LOXL2 and breast cancer: Pharmacological inhibition of LOX/LOXL2 abrogated the ECM network of CAF and significantly impeded tumor cell migration, like recent findings of CAF-LOXL2 function in breast cancer xenografts (81) and human gastric cancer cell lines (79).